Sarepta Therapeutics: BMO Capital Sees 168% Price Potential - Experts Indicate Increasing Acceptance of Elevidys

Sarepta Therapeutics (SRPT) (i.) has established itself as a leading company in precision gene therapy, particularly in the field of rare neuromuscular diseases such as Duchenne muscular dystrophy (DMD). The company already has several approved therapies on the market and boasts a comprehensive and diverse pipeline. Recent developments, including the approval and subsequent safety concerns regarding Elevidys, as well as a strategic realignment of the company, have brought the stock into the spotlight for investors and analysts. Current developments:...